Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Bain

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Journal of Hypertension|February 9, 2016
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trialJohn R Petrie, Steven P Marso, Stephen C Bain, et al.
Kidney International Reports|October 27, 2025
Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKDJanaka Karalliedde, Kieran McCafferty, Peter Winocour, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 17, 2024
Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelinesIndranil Dasgupta, Sagen Zac-Varghese, Khuram Chaudhry, et al.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
Diabetes, Obesity & Metabolism|October 5, 2018
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trialStephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, et al.
Eclinicalmedicine|January 21, 2025
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort studySafoora Gharibzadeh, Ash Routen, Cameron Razieh, et al.
Plos Genetics|October 3, 2012
New susceptibility loci associated with kidney disease in type 1 diabetesNiina Sandholm, Rany M Salem, Amy Jayne McKnight, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Journal of Hypertension|February 9, 2016
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trialJohn R Petrie, Steven P Marso, Stephen C Bain, et al.
Kidney International Reports|October 27, 2025
Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKDJanaka Karalliedde, Kieran McCafferty, Peter Winocour, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 17, 2024
Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelinesIndranil Dasgupta, Sagen Zac-Varghese, Khuram Chaudhry, et al.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
Diabetes, Obesity & Metabolism|October 5, 2018
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trialStephen C Bain, Ofri Mosenzon, Rosario Arechavaleta, et al.
Eclinicalmedicine|January 21, 2025
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort studySafoora Gharibzadeh, Ash Routen, Cameron Razieh, et al.
Plos Genetics|October 3, 2012
New susceptibility loci associated with kidney disease in type 1 diabetesNiina Sandholm, Rany M Salem, Amy Jayne McKnight, et al.
Pageof 13